International Journal for Research Trends in Social Science & Humanities
Volume 3 Issue 1
Jan-Feb 2025, PP 251-264

# Unveiling the Global Impact of Mpox: Challenges, Diagnosis, and Future Directions in Public Health

**Mr.Rajvardhan Chandravadan Ghatage[1], Ms. Tejaswini Shivaji Khot[2]**

Department B Pharmacy,

Shivraj College of Pharmacy Gadhinglaj[1]

Department B Pharmacy,

Institute Name:Women's College Of Pharmacy Peth-Vadgaon[2]

**Abstract.** Mpox, previously known as monkeypox, is a zoonotic viral disease caused by the monkeypox virus (MPXV), a member of the *Poxviridae* family. It is primarily found in regions of Central and West Africa, though recent outbreaks have raised concerns globally, including in non-endemic areas. Mpox presents with flu-like symptoms, followed by a characteristic rash, and can lead to severe health complications, especially in immunocompromised individuals. The disease is transmitted through direct contact with infected animals, humans, or contaminated materials, including bodily fluids and lesions. The initial signs of Mpox include fever, headache, muscle aches, and fatigue, followed by the appearance of a rash that typically begins on the face and spreads to other parts of the body. The lesions go through several stages before forming scabs and eventually falling off. While most cases are self-limiting, severe complications such as pneumonia, encephalitis, and secondary bacterial infections can occur, leading to increased morbidity and mortality. The case fatality rate varies between 1 to 10%, depending on the strain of the virus and the health status of the infected individual.The growing global concerns regarding the spread of Mpox have led to increased research into preventive measures, including vaccine development and antiviral treatments. Vaccines originally developed for smallpox have shown some cross-protection against Mpox, and the development of more specific vaccines and therapies is ongoing. Public health strategies focus on early diagnosis, contact tracing, isolation of affected individuals, and education to prevent transmission.This review explores the epidemiology, clinical features, diagnostic approaches, treatment options, and preventive strategies for Mpox, emphasizing the importance of global cooperation in controlling outbreaks and mitigating future risks of viral spillover events.

**Index Terms-** Mpox virus, Monkeypox outbreak, Zoonotic transmission, Poxviridae family, Mpox vaccination, Public health response.

## I. Introduction to Mpox Disease

Mpox, also known as monkeypox, is a viral infection caused by the monkeypox virus (MPXV), a member of the Orthopoxvirus Genus[1]. It is a zoonotic disease, meaning it can be transmitted from animals to humans[2]. The disease shares

similarities with smallpox, though it is generally less severe[1]. Symptoms of Mpox include fever, headache, muscle aches, fatigue, and a characteristic rash that progresses through various stages, including the formation of pustules, scabs, and eventually healing[2,3].

## II. History of Monkeypox

Monkeypox is a rare zoonotic viral disease caused by the monkeypox virus (MPXV), which was first discovered in laboratory monkeys in 1958[4]. This is where it gets its name, although the primary natural hosts are believed to be rodents and other small mammals[6]. The first human case of monkeypox was documented in 1970 in the Democratic Republic of Congo (DRC) during an effort to eradicate smallpox[5]. Over the next several years, human cases were reported sporadically across central and West Africa[6]. These outbreaks were typically small and confined to rural areas, with the disease primarily transmitted to humans through direct contact with infected animals or contaminated materials[7].The first recorded outbreak outside of Africa occurred in 2003 in the United States[9]. This unusual event involved 47 confirmed cases, primarily in individuals who had been in contact with pet prairie dogs that had been exposed to infected rodents[8]. This marked the first significant monkeypox outbreak outside Africa, prompting public health authorities to investigate the disease more closely[10]. Though the outbreak was contained, it raised concerns about the potential for monkeypox to spread beyond its usual endemic regions[9].In 2017, Nigeria experienced a major outbreak of monkeypox, with more than 200 suspected cases and over 100 confirmed cases[11]. This outbreak was notable because it led to a more thorough understanding of the disease's spread and highlighted the increasing risks of human-to-human transmission[7]. Since then, a handful of cases have been reported outside of Africa, with most being linked to travel or imported animals[12].The most significant event in the modern history of monkeypox came in May 2022, when the World Health Organization (WHO) confirmed multiple outbreaks in countries outside of Africa, including in Europe, North America, and Australia[11]. This marked the first widespread occurrence of monkeypox in non-endemic countries[9]. The outbreak prompted swift global responses, including increased surveillance, awareness campaigns, and vaccine distribution efforts as of mid-2022, hundreds of cases had been reported in over 30 countries[10].The history of monkeypox demonstrates the growing threat of zoonotic diseases, with an increasing number of human cases outside of endemic regions[9]. As global travel and wildlife interactions continue to rise, the spread of such diseases remains a significant public health concern[11].

## III. Global Health Security

Mpox, though historically not as widespread as diseases like COVID-19, has shown its ability to spread across different continents, as demonstrated by the 2022 outbreak[13]. Its potential to affect both endemic regions (West and Central Africa) and non-endemic regions (Europe, the United States) highlights its threat to global health security[15]. Understanding how the disease spreads, its symptoms, and preventive measures is essential to mitigate future risks and outbreaks[14].

**Cross-border Transmission:** In an increasingly globalized world with international travel and trade, infectious diseases like Mpox can travel across borders rapidly[16]. Outbreaks in non-endemic areas raise concerns about the ability of health systems to control such diseases[17]. The 2022 outbreak was a wake-up call about the importance of monitoring and detecting potential cross-border transmission early, and of having effective surveillance and response strategies[16].

**Vaccine and Treatment Development:** The current global health landscape emphasizes the need for rapid responses to emerging infectious diseases[18]. Mpox, although less lethal than other diseases like smallpox, can still cause serious health issues, especially in immunocompromised individuals[19,20]. Understanding Mpox and its pathophysiology is essential for developing more effective vaccines and treatments[18]. The JYNNEOS vaccine used for smallpox is also being used to combat monkeypox, but increased knowledge about the disease will drive the development of newer and more effective solutions[19].

**Public Health Infrastructure and Preparedness:** As the world recovers from the COVID-19 pandemic, strengthening public health infrastructure is critical[20]. The Mpox outbreak revealed gaps in readiness for emerging infectious diseases in many regions[21]. By studying the outbreak and understanding how Mpox spreads, public health systems can strengthen preparedness for future outbreaks, not only of Mpox but also other zoonotic diseases[22].

**Surveillance and Early Detection:** A better understanding of the disease's transmission, symptoms, and viral load will enhance early detection systems worldwide[23]. Improved surveillance systems, supported by real-time data sharing, will be critical in controlling the spread of Mpox and other infectious diseases[25]. Early identification and prompt intervention are key to limiting the impact of any outbreak[24].

**Social and Economic Impact:** The pandemic of the past few years has highlighted the social and economic consequences of infectious disease outbreaks[26]. Although Mpox may not have the same broad economic impact as COVID-19, it can disrupt health systems, economies, and communities, particularly if control measures (such as quarantine or isolation) become widespread[28]. Understanding the disease will help mitigate unnecessary panic and economic disruption by facilitating informed decision-making[27].

**Public Awareness and Education:** Misinformation can spread rapidly during outbreaks, complicating public health responses[29]. Educating the public about Mpox, its transmission, and preventive measures helps curb fear and promotes better hygiene practices and vaccination uptake[11]. This in turn helps to limit the spread of the disease and saves lives[31]. A well-informed population is an essential pillar in controlling any outbreak[30].

International Journal for Research Trends in Social Science & Humanities
Volume 3 Issue 1
Jan-Feb 2025, PP 251-264

## IV. Signs and Symptoms of Mpox

Monkeypox (Mpox) typically begins with early signs such as fever, headache, muscle aches, chills, and swollen lymph nodes[32]. These symptoms can appear within 5 to 21 days after exposure to the virus[33]. In addition to the systemic symptoms, individuals may also experience fatigue, back pain, and malaise[32].A characteristic rash soon follows, usually starting on the face and spreading to other parts of the body, including the palms, soles of the feet, and genital area[33]. The rash begins as flat red spots (macules), which then turn into raised bumps (papules), followed by fluid-filled blisters (vesicles), pustules, and finally, scabs that eventually fall off[34]. This progression of the rash typically occurs over the course of 2 to 4 weeks[32,33].The duration of symptoms generally lasts for 2 to 4 weeks, with the worst symptoms typically observed during the first week, after which the rash begins to scab and heal[35]. While the disease is often self-limited, it can cause severe complications in some cases, especially in immunocompromised individuals or those with underlying health conditions[34]. Supportive care is usually provided for symptom management, and antiviral treatments may be administered in severe cases[35].

Table 1.Signs, Symptoms and duration of Mpox[36]

| Sr.No. | Early Signs & Symptoms | Duration |
|---|---|---|
| 1. | Fever | 2 to 4 days |
| 2. | Headache | 2 to 3 days |
| 3. | Muscle Aches (Myalgia) | 2 to 4 days |
| 4. | Chills | 1 to 2 days |
| 5. | Fatigue (Lethargy) | 3 to 7 days |
| 6. | Swollen Lymph Nodes | 3 to 7 days |
| 7. | Sore Throat | 2 to 4 days |
| 8. | Cough | 2 to 3 days |
| 9. | Skin Rash | 2 to 4 days |
| 10. | General Malaise | 3 to 5 days |

**Clinical Research of Mpox Disease**

Mpox (Monkeypox) has gained global attention due to its emergence outside endemic regions in recent years, particularly in 2022 when cases spread to non-endemic countries[37]. Clinical research into Mpox focuses on understanding the

disease's clinical progression, effective treatments, vaccine development, transmission dynamics, and strategies for prevention and control[38].

**Clinical Epidemiology and Pathogenesis:** Clinical research has revealed key insights into the epidemiology and pathogenesis of Mpox[39]. It is caused by the Mpox virus, a member of the Orthopoxvirus genus in the Poxviridae family[40]. Understanding the virus's transmission dynamics, clinical manifestations, and pathophysiology are essential for effective clinical management[41].Research has shown that Mpox presents similarly to smallpox, with an incubation period of 7-14 days, followed by flu-like symptoms such as fever, headache, and fatigue[39]. These symptoms are followed by a characteristic rash that progresses from macules to papules, vesicles, pustules, and eventually scabs[40]. Notably, Mpox causes lymphadenopathy (swollen lymph nodes), which distinguishes it from other poxvirus diseases.

**Treatment and Antiviral Therapy**

While Mpox typically resolves on its own without specific antiviral treatment, there is an increasing need for effective treatment protocols, particularly in immunocompromised individuals or in severe cases[41]. Clinical research has focused on identifying existing antiviral drugs and their efficacy in treating Mpox[42].

**Tecovirimat (TPOXX)**

Clinical trials and research suggest that Tecovirimat, an antiviral drug developed for smallpox, has shown effectiveness against the Mpox virus[43]. It works by inhibiting the virus's ability to spread from cell to cell[45]. A study published in 2021 demonstrated that Tecovirimat shortened the time to recovery and improved clinical outcomes in patients infected with orthopoxviruses, including Mpox[44].

**Cidofovir:** Cidofovir, another antiviral agent, has been evaluated for its ability to treat poxvirus infections, including Mpox[42]. Though primarily used to treat cytomegalovirus (CMV) infections, research has indicated that it might also be effective against Mpox by inhibiting viral DNA polymerase[43].

**Vaccinia Immune Globulin (VIG):** For patients experiencing severe complications or those at high risk, VIG has been considered as a treatment option[45]. VIG is an immunoglobulin product derived from individuals who have been vaccinated against smallpox and can be used to mitigate the effects of poxvirus infections[44].

**Vaccine Development and Efficacy**

Vaccination has been a critical strategy for preventing Mpox, especially in individuals in high-risk categories or those exposed to the virus in outbreak settings[51]. Smallpox vaccines have demonstrated cross-protection against Mpox due to the genetic similarity between the two viruses[50]. Research on newer vaccines, such as the Modified Vaccinia Ankara (MVA) vaccine and ACAM2000, has been pivotal[51].

**MVA-BN Vaccine:** This vaccine has been used to protect against smallpox and is being evaluated for use against Mpox[52]. It has shown safety and efficacy in clinical trials, offering promise as a preventive measure in high-risk populations[53].

**ACAM2000 Vaccine:** ACAM2000, another smallpox vaccine, has also demonstrated effectiveness in preventing Mpox[54]. However, its use may be limited in certain populations due to potential side effects associated with the vaccine[55].

**Treatment and Management:** The treatment and management of Mpox primarily involve supportive care, with the focus on alleviating symptoms, managing complications, and preventing further transmission[36]. As a zoonotic disease caused by the Mpox virus (a member of the Orthopoxvirus genus), its management is still evolving, particularly in the context of its spread outside endemic regions in recent years[37].

**Supportive Care:** In many cases, Mpox is a self-limiting illness, meaning that it may resolve on its own without the need for specific antiviral treatment[46]. Supportive care is the cornerstone of management, especially for individuals with mild cases[47]. This includes:

**Fever Management:** Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or paracetamol (acetaminophen) can be used to reduce fever and discomfort[48].

**Hydration:** Oral rehydration or intravenous fluids may be necessary to maintain hydration, especially if the patient has diarrhea or excessive fluid loss[49].

**Pain Management:** Topical ointments, corticosteroids, or over-the-counter pain relievers can help relieve itching and pain from the rash and skin lesions[51].

**Antiviral Treatment:** While Mpox typically resolves on its own, antiviral therapies are being explored to manage severe cases or those with complications[56]. Several antiviral agents have shown promise in preclinical studies and clinical trials, although none are specifically approved for Mpox as of now[52].

**Isolation and Infection Control:** Preventing the spread of Mpox is a critical component of managing outbreaks[55]. Since the virus spreads through close contact with infected animals, humans, or contaminated materials, isolation and infection control practices are essential[56].

**Isolation of Infected Patients:** Individuals diagnosed with Mpox should be isolated in healthcare settings until they are no longer contagious, typically when their lesions have healed and scabs have fallen off[57]. This helps prevent human-to-human transmission[58].

**Use of Personal Protective Equipment (PPE):** Healthcare workers must use appropriate PPE, including gloves, gowns, masks, and eye protection, when handling Mpox-infected patients to prevent direct contact with bodily fluids or lesions[59].

**Quarantine Measures:** In the event of an outbreak, quarantine measures may be implemented for individuals who have had close contact with infected persons[45]. This helps reduce the risk of further spread[60].

**Management of Complications:** Though Mpox is typically a self-limiting disease, it can cause complications in certain individuals, especially those who are immune compromised, pregnant, or young children[61]. Severe complications include bacterial infections of the skin lesions, pneumonia, sepsis, and encephalitis[60].

- **Secondary Bacterial Infections:** The open lesions of Mpox can become infected with bacteria, leading to abscesses or cellulitis[62]. These can be treated with appropriate antibiotics[62].
- **Pneumonia and Respiratory Distress:** In some cases, the virus can cause respiratory distress, requiring supportive respiratory care, including oxygen therapy or mechanical ventilation[63].
- **Encephalitis:** In rare cases, Mpox can lead to encephalitis (inflammation of the brain), which requires urgent medical attention and may require antiviral medications, corticosteroids, or other therapies to manage inflammation[64].
- **Pregnancy and Mpox:** Pregnant women are at higher risk for severe complications, including miscarriage or stillbirth[65]. If a pregnant woman contracts Mpox, close monitoring and supportive care are necessary to protect both the mother and the fetus[67].

**Public Health Challenges During an Outbreak:** When Mpox outbreaks occur, public health systems often face overwhelming challenges in tracking, isolating, and containing the virus[66]. The initial symptoms of Mpox fever, swollen lymph nodes, and rashes can resemble other infectious diseases like chickenpox, measles, or even COVID-19[67]. This makes diagnosis and early detection more difficult, particularly in areas without robust diagnostic infrastructure[68].

**Delayed Diagnosis and Misdiagnosis:** In settings with limited healthcare resources, there may be a delay in recognizing Mpox cases[65]. Misdiagnosis can further complicate efforts to curb transmission, as individuals who are infected may not be immediately isolated or given appropriate care[66].

**Infection Control:** The virus spreads through close contact with infected individuals or contaminated materials[68]. Effective isolation and quarantine protocols are essential, but these measures can be difficult to enforce, particularly in communities where healthcare infrastructure is already overburdened[67].

**Limited Availability of Vaccines and Antivirals:** Despite the availability of smallpox vaccines (which also provide protection against Mpox), the global stockpiles of vaccines are limited[71]. Moreover, the antiviral agents currently available, such as Tecovirimat, are not widely accessible or approved for general use in many countries, leaving health systems with few treatment options for those who develop severe cases of the disease[70].

**Vaccine Availability:** Although vaccines such as Modified Vaccinia Ankara (MVA) are used to prevent smallpox, they are not always readily available, especially in low-income countries[68]. The logistical challenges in distribution, limited vaccine stockpiles, and the cold storage requirements for some vaccines make rapid deployment difficult in outbreak situations[7].

**Antiviral Treatment:** The antiviral drugs available to treat Mpox are either still under study or are not easily accessible to the general population[11]. The lack of approved and widely accessible antivirals for Mpox adds to the difficulties in managing severe cases and preventing long-term complications[8].

**Stigma and Misinformation Surrounding the Disease:** One of the critical challenges in managing Mpox outbreaks is the stigma and misinformation surrounding the disease[44]. Like many emerging infectious diseases, Mpox often triggers fears and misconceptions that hinder effective communication and public health response[44].

**Stigmatization:** In some regions, Mpox has been associated with certain populations, especially those who have close contact with infected animals or are in communities with a high incidence of cases[11]. This can result in discrimination and social isolation, which may deter individuals from seeking timely medical care[6].

**Misinformation and Rumors:** In the era of social media, misinformation about the disease can spread quickly[70]. False information about how the disease is transmitted, its severity, or how it can be prevented can exacerbate the public health crisis[8]. Misinformation can also create panic, leading to a lack of trust in healthcare systems and public health advice[16].

**Challenges in Public Health Messaging:** Health authorities must navigate a landscape where misinformation and fears surrounding Mpox can overshadow efforts to educate the public about prevention and treatment[1]. Effective public health messaging that addresses misconceptions, educates the public, and promotes the importance of early detection and vaccination is critical[54].

**Global Health Inequalities Affecting Outbreak Control:** Global health inequalities are another major challenge in controlling Mpox outbreaks[7]. The ability to respond effectively to a disease outbreak is heavily dependent on the infrastructure, resources, and healthcare systems available in a particular region[51]. Low-income countries, especially those with limited access to healthcare, are more vulnerable to widespread outbreaks due to factors such as:

**Limited Healthcare Infrastructure:** Many regions with limited access to healthcare are unable to provide timely diagnosis, appropriate treatment, or isolation measures for those infected with Mpox[19]. These areas may also lack the necessary laboratory facilities to confirm suspected cases, leading to delays in response[30].

**Access to Vaccines and Antivirals:** Access to vaccines, antivirals, and other critical medical resources is often inequitable, with wealthier countries securing

access to stockpiles before low-income nations can obtain supplies[50]. This exacerbates global health disparities and hinders efforts to prevent or control Mpox outbreaks in resource-poor settings[29].

**Global Mobility:** As the world becomes more interconnected, the spread of diseases like Mpox from endemic to non-endemic regions is increasingly likely[18]. Migrants and travelers from high-risk areas may introduce the virus to new regions, complicating control efforts[69].

**Economic Constraints:** Many low- and middle-income countries may not have the financial resources to effectively manage an Mpox outbreak[65]. The high costs of vaccines, antivirals, diagnostic tools, and healthcare services can overwhelm national health budgets, especially in countries facing other pressing health crises[70].

## V. Conclusion

Mpox, a zoonotic viral infection caused by the monkeypox virus, has become a significant global public health concern due to its reemergence in non-endemic areas. The disease, characterized by symptoms such as fever, fatigue, and a distinctive rash, has highlighted vulnerabilities in our current systems of disease surveillance and response. Though typically confined to Central and West Africa, recent outbreaks across the globe have underscored the need for stronger international cooperation and enhanced preparedness to control potential health crises.While there is still much to learn about the virus, recent advancements in diagnostics, vaccines, and treatments are paving the way for better management of future outbreaks. The smallpox vaccine has shown promise in providing protection against the disease, and antiviral agents are currently under research to better treat infected individuals.The importance of early detection, rigorous public health interventions, and effective public awareness campaigns cannot be overstated. The stigma surrounding Mpox, alongside misinformation, has further complicated containment efforts, making education a crucial tool in reducing transmission. As Mpox continues to be monitored globally, there is an urgent need for improved international coordination and investment in research to better understand the virus, its transmission dynamics, and how best to prevent and treat it. Only through collaborative efforts, robust healthcare infrastructure, and continued vigilance can we effectively manage and reduce the impact of Mpox on global health.

## References

1. Thornhill, J. P., Gandhi, M., & Orkin, C. (2024). Mpox: The Reemergence of an Old Disease and Inequities. Annual Review of Medicine, 75(1), 159-175.
2. Deputy, N. P., Deckert, J., Chard, A. N., Sandberg, N., Moulia, D. L., Barkley, E., ... & Feldstein, L. R. (2023). Vaccine effectiveness of JYNNEOS against mpox disease in the United States. New England Journal of Medicine, 388(26), 2434-2443.
3. Titanji, B. K., Hazra, A., & Zucker, J. (2024). Mpox clinical presentation, diagnostic approaches, and treatment strategies: a review. JAMA.

4. Aldred, B., Lyles, R. H., Scott, J. Y., Gromer, D. J., Aldredge, A., Workowski, K. A., ... & Cantos, V. D. (2024). Early tecovirimat treatment for mpox disease among people with HIV. JAMA Internal Medicine, 184(3), 275-279.
5. Sharma, E., Malhotra, S., Kaul, S., Jain, N., & Nagaich, U. (2023). Unveiling the Mpox menace: Exploring the intricacies of a zoonotic virus and clinical implications. Diagnostic Microbiology and Infectious Disease, 116024.
6. Maronese, C. A., Avallone, G., Aromolo, I. F., Spigariolo, C. B., Quattri, E., Ramoni, S., ... & Marzano, A. V. (2023). Mpox: an updated review of dermatological manifestations in the current outbreak. British Journal of Dermatology, 189(3), 260-270.
7. Anil, S., Joseph, B., Thomas, M., Sweety, V. K., Suresh, N., & Waltimo, T. (2024). Monkeypox: a viral zoonotic disease of rising global concern. Infectious Diseases & Immunity, 4(03), 121-131.
8. Protopapas, K., Dimopoulou, D., Kalesis, N., Akinosoglou, K., & Moschopoulos, C. D. (2024). Mpox and Lessons Learned in the Light of the Recent Outbreak: A Narrative Review. Viruses, 16(10), 1620.
9. Mortier, C., Tissot-Dupont, H., Cardona, F., Bruel, C., Lahouel, S., Lasri, H., ... & Cassir, N. (2023). How to distinguish mpox from its mimickers: An observational retrospective cohort study. Journal of Medical Virology, 95(10), e29147.
10. Chauhan, R. P., Fogel, R., & Limson, J. (2023). Overview of diagnostic methods, disease prevalence and transmission of MPOX (formerly monkeypox) in humans and animal reservoirs. Microorganisms, 11(5), 1186.
11. Mattiuzzi, C., Henry, B. M., Rizk, J. G., & Lippi, G. (2024). Mpox (monkeypox) diagnostic kits–September 2024. Diagnosis, (0).
12. Yon, H., Shin, H., Shin, J. I., Shin, J. U., Shin, Y. H., Lee, J., ... & Yon, D. K. (2023). Clinical manifestations of human mpox infection: a systematic review and meta-analysis. Reviews in medical virology, 33(4), e2446.
13. Sukhdeo, S., Mishra, S., & Walmsley, S. (2022). Human monkeypox: a comparison of the characteristics of the new epidemic to the endemic disease. BMC infectious diseases, 22(1), 928.
14. León-Figueroa, D. A., Barboza, J. J., Siddiq, A., Sah, R., Valladares-Garrido, M. J., & Rodriguez-Morales, A. J. (2024). Knowledge and attitude towards mpox: Systematic review and meta-analysis. Plos one, 19(8), e0308478.
15. Hazra, A., Zucker, J., Bell, E., Flores, J., Gordon, L., Mitjà, O., ... & Marchetta, L. (2024). Mpox in people with past infection or a complete vaccination course: a global case series. The Lancet Infectious Diseases, 24(1), 57-64.
16. Edenborough, K., Aziz, A., Sexton-Oates, N., Savic, I., Steinig, E., Quinn, B., ... & Lim, C. K. (2024). Mpox genomics in outbreak control: challenges and limitations. The Lancet Microbe.
17. Khan, S. U. R., Asif, S., Bilal, O., & Ali, S. (2024). Deep hybrid model for Mpox disease diagnosis from skin lesion images. International Journal of Imaging Systems and Technology, 34(2), e23044.
18. Damaso, C. R. (2023). Phasing out monkeypox: mpox is the new name for an old disease. The Lancet Regional Health–Americas, 17.
19. Pischel, L., Martini, B. A., Yu, N., Cacesse, D., Tracy, M., Kharbanda, K., ... & Omer, S. B. (2024). Vaccine effectiveness of 3rd generation mpox vaccines

against mpox and disease severity: A systematic review and meta-analysis. Vaccine.
20. Ahmed, S. K., Mohamed, M. G., Dabou, E. A., Abuijlan, I., Chandran, D., El-Shall, N. A., ... & Dhama, K. (2023). Monkeypox (mpox) in immunosuppressed patients. F1000Research, 12, 127.
21. Jiang, L., Xu, A., Guan, L., Tang, Y., Chai, G., Feng, J., ... & Fan, H. (2024). A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies. In Exploration (p. 20230112).
22. Satapathy, P., Khatib, M. N., Gaidhane, S., Zahiruddin, Q. S., Alrasheed, H. A., Al-Subaie, M. F., ... & Sah, R. (2024). Multi-organ clinical manifestations of Mpox: an umbrella review of systematic reviews. BMC Infectious Diseases, 24(1), 992.
23. Wei, Z. K., Zhao, Y. C., Wang, Z. D., Sui, L. Y., Zhao, Y. H., & Liu, Q. (2023). Animal models of mpox virus infection and disease. Infectious Medicine, 2(3), 153-166.
24. Lu, J., Xing, H., Wang, C., Tang, M., Wu, C., Ye, F., ... & Shen, L. (2023). Mpox (formerly monkeypox): pathogenesis, prevention, and treatment. Signal Transduction and Targeted Therapy, 8(1), 458.
25. Brochero, C. D., Nocua-Báez, L. C., Cortes, J. A., Charniga, K., Buitrago-Lopez, A., & Cucunubá, Z. M. (2025). Decoding mpox: a systematic review and meta-analysis of the transmission and severity parameters of the 2022–2023 global outbreak. BMJ Global Health, 10(1).
26. Oghuan, J., Chavarria, C., Vanderwal, S. R., Gitter, A., Ojaruega, A. A., Monserrat, C., ... & Wu, F. (2023). Wastewater analysis of Mpox virus in a city with low prevalence of Mpox disease: an environmental surveillance study. The Lancet Regional Health–Americas, 28.
27. Collins, O. C., & Duffy, K. J. (2024). Dynamics and control of mpox disease using two modelling approaches. Modeling Earth Systems and Environment, 10(2), 1657-1669.
28. Chauhan, R. P., Fogel, R., & Limson, J. (2023). Overview of diagnostic methods, disease prevalence and transmission of MPOX (formerly monkeypox) in humans and animal reservoirs. Microorganisms, 11(5), 1186.
29. Cowen, E. W., Tkaczyk, E. R., Norton, S. A., & Leslie, K. S. (2023). Mpox—a rapidly evolving disease. JAMA dermatology, 159(4), 424-431.
30. Mitjà, O., Alemany, A., Marks, M., Mora, J. I. L., Rodríguez-Aldama, J. C., Silva, M. S. T., ... & Paredes, M. T. (2023). Mpox in people with advanced HIV infection: a global case series. The Lancet, 401(10380), 939-949.
31. Satapathy, P., Shamim, M. A., Padhi, B. K., Gandhi, A. P., Sandeep, M., Suvvari, T. K., ... & Sah, R. (2024). Mpox virus infection in women and outbreak sex disparities: A Systematic Review and Meta-analysis. Communications Medicine, 4(1), 188.
32. Laurenson-Schafer, H., Sklenovská, N., Hoxha, A., Kerr, S. M., Ndumbi, P., Fitzner, J., ... & de Waroux, O. L. P. (2023). Description of the first global outbreak of mpox: an analysis of global surveillance data. The Lancet Global Health, 11(7), e1012-e1023.
33. Pan, D., Nazareth, J., Sze, S., Martin, C. A., Decker, J., Fletcher, E., ... & Tang, J. W. (2023). Transmission of monkeypox/mpox virus: a narrative review of

environmental, viral, host, and population factors in relation to the 2022 international outbreak. Journal of medical virology, 95(2), e28534.
34. Ogoina, D., Dalhat, M. M., Denue, B. A., Okowa, M., Chika-Igwenyi, N. M., Yusuff, H. A., ... & Adeiza, M. A. (2023). Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study. The Lancet Infectious Diseases, 23(12), 1418-1428.
35. Cevik, M., Tomori, O., Mbala, P., Scagliarini, A., Petersen, E., Low, N., ... & Blumberg, L. (2024). The 2023–2024 multi-source mpox outbreaks of Clade I MPXV in sub-Saharan Africa: alarm bell for Africa and the World. IJID One Health, 4.
36. van Ewijk, C. E., Miura, F., van Rijckevorsel, G., de Vries, H. J., Welkers, M. R., van den Berg, O. E., ... & Franz, E. (2023). Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine. Eurosurveillance, 28(12), 2200772.
37. Liu, Q., Fu, L., Wang, B., Sun, Y., Wu, X., Peng, X., ... & Zou, H. (2023). Clinical characteristics of human Mpox (monkeypox) in 2022: a systematic review and meta-analysis. Pathogens, 12(1), 146.
38. Rivers, C., Watson, C., & Phelan, A. L. (2024). The resurgence of Mpox in Africa. JAMA, 332(13), 1045-1046.
39. Yon, H., Shin, H., Shin, J. I., Shin, J. U., Shin, Y. H., Lee, J., ... & Yon, D. K. (2023). Clinical manifestations of human mpox infection: a systematic review and meta-analysis. Reviews in medical virology, 33(4), e2446.
40. Hazra, A., Zucker, J., Bell, E., Flores, J., Gordon, L., Mitjà, O., ... & Marchetta, L. (2024). Mpox in people with past infection or a complete vaccination course: a global case series. The Lancet Infectious Diseases, 24(1), 57-64.
41. Fink, D. L., Callaby, H., Luintel, A., Beynon, W., Bond, H., Lim, E. Y., ... & Kilbride, E. (2023). Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study. The Lancet Infectious Diseases, 23(5), 589-597.
42. Mitjà, O., Alemany, A., Marks, M., Mora, J. I. L., Rodríguez-Aldama, J. C., Silva, M. S. T., ... & Paredes, M. T. (2023). Mpox in people with advanced HIV infection: a global case series. The Lancet, 401(10380), 939-949.
43. Wawina-Bokalanga, T., Akil-Bandali, P., Kinganda-Lusamaki, E., Lokilo, E., Jansen, D., Amuri-Aziza, A., ... & Mbala-Kingebeni, P. (2024). Co-circulation of monkeypox virus subclades Ia and Ib in Kinshasa Province, Democratic Republic of the Congo, July to August 2024. Eurosurveillance, 29(38), 2400592
44. Wawina-Bokalanga, T., Akil-Bandali, P., Kinganda-Lusamaki, E., Lokilo, E., Jansen, D., Amuri-Aziza, A., ... & Mbala-Kingebeni, P. (2024). Co-circulation of monkeypox virus subclades Ia and Ib in Kinshasa Province, Democratic Republic of the Congo, July to August 2024. Eurosurveillance, 29(38), 2400592.
45. Chauhan, R. P., Fogel, R., & Limson, J. (2023). Overview of diagnostic methods, disease prevalence and transmission of MPOX (formerly monkeypox) in humans and animal reservoirs. Microorganisms, 11(5), 1186.
46. Ulaeto, D., Agafonov, A., Burchfield, J., Carter, L., Happi, C., Jakob, R., ... & Lewis, R. F. (2023). New nomenclature for mpox (monkeypox) and monkeypox virus clades. The Lancet Infectious Diseases, 23(3), 273-275.

47. Hatami, H., Jamshidi, P., Arbabi, M., Safavi-Naini, S. A. A., Farokh, P., Izadi-Jorshari, G., ... & Sechi, L. A. (2023). Demographic, epidemiologic, and clinical characteristics of human monkeypox disease pre-and post-2022 outbreaks: a systematic review and meta-analysis. Biomedicines, 11(3), 957.
48. Masirika, L. M., Udahemuka, J. C., Schuele, L., Ndishimye, P., Otani, S., Mbiribindi, J. B., ... & Siangoli, F. B. (2024). Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. Eurosurveillance, 29(11), 2400106.
49. Jain, N., Lansiaux, E., & Simanis, R. (2022). The new face of monkeypox virus: an emerging global emergency. New microbes and new infections, 47.
50. Kibungu, E. M., Vakaniaki, E. H., Kinganda-Lusamaki, E., Kalonji-Mukendi, T., Pukuta, E., Hoff, N. A., ... & International Mpox Research Consortium. (2024). Clade I–associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerging Infectious Diseases, 30(1), 172.
51. Pinto, P., Costa, M. A., Gonçalves, M. F., Rodrigues, A. G., & Lisboa, C. (2023). Mpox person-to-person transmission—where have we got so far? a systematic review. Viruses, 15(5), 1074.
52. Gao, L., Shi, Q., Dong, X., Wang, M., Liu, Z., & Li, Z. (2023). Mpox, Caused by the MPXV of the Clade IIb lineage, goes global. Tropical Medicine and Infectious Disease, 8(2), 76.
53. Rabaan, A. A., Alasiri, N. A., Aljeldah, M., Alshukairiis, A. N., AlMusa, Z., Alfouzan, W. A., ... & Imran, M. (2023). An updated review on monkeypox viral disease: emphasis on genomic diversity. Biomedicines, 11(7), 1832.
54. Adepoju, P. (2024). Mpox declared a public health emergency. The Lancet, 404(10454), e1-e2.
55. Miura, F., Backer, J. A., van Rijckevorsel, G., Bavalia, R., Raven, S., Petrignani, M., ... & Wallinga, J. (2024). Time scales of human mpox transmission in the Netherlands. The Journal of Infectious Diseases, 229(3), 800-804.
56. Zinnah, M. A., Uddin, M. B., Hasan, T., Das, S., Khatun, F., Hasan, M. H., ... & Ashour, H. M. (2024). The re-emergence of mpox: old illness, modern challenges. Biomedicines, 12(7), 1457.
57. Vakaniaki, E. H., Kacita, C., Kinganda-Lusamaki, E., O'Toole, Á., Wawina-Bokalanga, T., Mukadi-Bamuleka, D., ... & Mbala-Kingebeni, P. (2024). Sustained Human Outbreak of a New MPXV Clade I Lineage in the Eastern Democratic Republic of the Congo. Nature Medicine, 1-1.
58. Yang, Z. (2022). Monkeypox: A potential global threat?. Journal of medical virology, 94(9), 4034.
59. Sulaiman, S. K., Isma'il Tsiga-Ahmed, F., Musa, M. S., Makama, B. T., Sulaiman, A. K., & Abdulaziz, T. B. (2024). Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis. Communications Medicine, 4(1), 136.
60. Palich, R., Burrel, S., Monsel, G., Nouchi, A., Bleibtreu, A., Seang, S., ... & Pourcher, V. (2023). Viral loads in clinical samples of men with monkeypox virus infection: a French case series. The Lancet Infectious Diseases, 23(1), 74-80.

61. Gupta, A. K., Talukder, M., Rosen, T., & Piguet, V. (2023). Differential diagnosis, prevention, and treatment of mpox (monkeypox): a review for dermatologists. American Journal of Clinical Dermatology, 24(4), 541-556.
62. Mileto, D., Riva, A., Cutrera, M., Moschese, D., Mancon, A., Meroni, L., ... & Antinori, S. (2022). New challenges in human monkeypox outside Africa: A review and case report from Italy. Travel medicine and infectious disease, 49, 102386.
63. Zhou, Y., & Chen, Z. (2023). Mpox: a review of laboratory detection techniques. Archives of virology, 168(8), 221.
64. Okwor, T., Mbala, P. K., Evans, D. H., & Kindrachuk, J. (2023). A contemporary review of clade-specific virological differences in monkeypox viruses. Clinical Microbiology and Infection.
65. Likos, A. M., Sammons, S. A., Olson, V. A., Frace, A. M., Li, Y., Olsen-Rasmussen, M., ... & Damon, I. K. (2005). A tale of two clades: monkeypox viruses. Journal of General Virology, 86(10), 2661-2672.
66. Colavita, F., Antinori, A., Nicastri, E., Focosi, D., Girardi, E., Vaia, F., & Maggi, F. (2022). Monkeypox virus in human body sites and fluids: evidence for transmission. The Lancet. Infectious Diseases, 23(1), 6.
67. Silva, M. S. T., Coutinho, C., Torres, T. S., Peixoto, E., Ismério, R., Lessa, F., ... & Pereira, S. A. (2023). Ambulatory and hospitalized patients with suspected and confirmed mpox: an observational cohort study from Brazil. The Lancet Regional Health–Americas, 17.
68. Antunes, F., Cordeiro, R., & Virgolino, A. (2022). Monkeypox: from a neglected tropical disease to a public health threat. Infectious Disease Reports, 14(5), 772-783.
69. Paredes, M. I., Ahmed, N., Figgins, M., Colizza, V., Lemey, P., McCrone, J. T., ... & Bedford, T. (2024). Underdetected dispersal and extensive local transmission drove the 2022 mpox epidemic. Cell, 187(6), 1374-1386.
70. Karagoz, A., Tombuloglu, H., Alsaeed, M., Tombuloglu, G., AlRubaish, A. A., Mahmoud, A., ... & Alsuhaimi, E. (2023). Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. Journal of infection and public health, 16(4), 531-541.